Evidence map›Paper›PMID 35677170›Full record

ArticleFrontiers in oncology2022

Establishment of Organoids From Human Epithelioid Sarcoma With the Air-Liquid Interface Organoid Cultures.

Toru Wakamatsu, Hisataka Ogawa, Keiichi Yoshida, Yukiko Matsuoka, Kazuko Shizuma, Yoshinori Imura, Hironari Tamiya, Sho Nakai, Toshinari Yagi, Shigenori Nagata and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Toru WakamatsuDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Hisataka OgawaNitto joint Research Department for Nucleic Acid Medicine, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Keiichi YoshidaNext-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
Yukiko MatsuokaNext-generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
Kazuko ShizumaNitto joint Research Department for Nucleic Acid Medicine, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Yoshinori ImuraDepartment of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Hironari TamiyaDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Sho NakaiDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Toshinari YagiDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Shigenori NagataDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Yoshihiro YuiSarcoma Treatment Laboratory, Research Institute, Nozaki Tokushukai Hospital, Osaka, Japan.
Satoru SasagawaMolecular Biology Laboratory, Research Institute, Nozaki Tokushukai Hospital, Osaka, Japan.
Satoshi TakenakaDepartment of Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Osaka University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPFukuoka Tokushukai Hospital · JPNitto (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although biological resources are essential for basic and preclinical research in the oncological field, those of sarcoma are not sufficient for rapid development of the treatment. So far, some sarcoma cell lines have been established, however, the success rate was low and the established sarcoma types were frequently biased. Therefore, an efficient culture method is needed to determine the various types of sarcomas. Organoid culture is a 3-dimentional culture method that enables the recapitulation of the tumor microenvironment and the success rate reported is higher than the 2-dimentional culture. The purpose of this study was to report our newly established organoids from human epithelioid sarcoma using the air-liquid interface organoid culture method. Methods: We treated 2 patients with epithelioid sarcoma in our institute. The remaining sarcoma specimens after surgical resection were embedded in collagen type 1 gels according to the air-liquid interface organoid culture method. After serial passages, we xenografted the organoids to NOD-scid IL2Rgnull (NSG) mice. Using the developed tumors, we performed histological and genomic analyses to compare the similarities and differences with the original epithelioid sarcoma from the patient. Results: Organoids from the epithelioid sarcoma could be serially cultured and maintained in collagen type 1 gels for more than 3 passages. Developed orthotopic tumor xenografts were detected in the NSG mice. After the process was repeated severally, the patient derived organoid lines from the epithelioid sarcoma were established. The established organoids showed loss of integrase interactor 1 expression with polymerase chain reaction and immunohistochemical analyses. The xenografted organoids of the epithelioid sarcoma had histologically similar phenotypes with the original tumor and genetically resembled it to some degree. Conclusions: The present study demonstrated 2 novel established organoid models of epithelioid sarcoma, and our organoid models could be used to investigate the molecular pathogenesis and develop a novel treatment.

Indexed as

air-liquid interface organoid culture methodepithelioid sarcomaintegrase interactor 1organoidxenograft

Identifiers

PMID35677170
PMCPMC9169059
OpenAlexW4281289115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.